JSPR - PR: Jasper Therapeutics Announces Merger with Kira Pharmaceuticals -Combined company positioned to advance portfolio of biologic agen
JSPR - PR: Jasper Therapeutics Announces Merger with Kira Pharmaceuticals -Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders -Concurrent $132M private investment with participation from leading Life Sciences investors and Mirador Therapeutics -Kira out-licenses KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small molecule C5a receptor antagonist, to Mirador Therapeutics, for $12M upon signing and potential development and sales milestone payments
JSPR - PR: Jasper Therapeutics Announces Merger with Kira Pharmaceuticals -Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders -Concurrent $132M private investment with participation from leading Life Sciences investors and Mirador Therapeutics -Kira out-licenses KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small molecule C5a receptor antagonist, to Mirador Therapeutics, for $12M upon signing and potential development and sales milestone payments